Clinical outcomes with MiniMedTM 780G Advanced Hybrid Closed Loop Therapy in 2- to 6-year-old children with Type 1 diabetes

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
6 Downloads (Pure)

Abstract

Advanced hybrid closed loop (AHCL) therapy with the Medtronic MiniMedTM 780G system improves glycemia, however the clinical outcomes in younger children remain less established. This pilot study aimed to explore the CGM metrics while on AHCL in very young children. Children between two and seven years of age and on insulin pump therapy were recruited. A 2-week phase in Manual Mode was followed by a 6-week AHCL phase. CGM metrics were analyzed to review glycemic outcomes. Out of 11 participants enrolled [mean (SD) age 5.3 (0.8) years), 10 completed the study. Time in closed loop was 96.7 (3.9)%. In AHCL, participants had a mean (SD) time in range of 72.6 (7.4)% and spent 3.0 (1.74 )% and 0.63 (0.46)% in time < 70 mg/dl and < 54 mg/dl respectively. AHCL is a feasible option for management of young children with type 1 diabetes.

Original languageEnglish
JournalDiabetes Technology & Therapeutics
Volume26
Issue number5
DOIs
Publication statusE-pub ahead of print - 30 Apr 2024

Fingerprint

Dive into the research topics of 'Clinical outcomes with MiniMedTM 780G Advanced Hybrid Closed Loop Therapy in 2- to 6-year-old children with Type 1 diabetes'. Together they form a unique fingerprint.

Cite this